Acadia Pharmaceuticals (ACAD US): No Hallucination; Clear Path of Accelerated Growth Ahead
Acadia is well-positioned to report accelerated double-digit revenue growth through 2025 driven by new Rett syndrome drug launch in the US and...
463 Views
Neuren Pharmaceuticals (NEU AU): It’s Not Too Late to Join the Bandwagon; More Stream Is Still Left
Neuren’s North American partner gained FDA approval for its first drug, triggering milestone and royalty payment. Reasonable valuation and upcoming...
433 Views
SK Biopharm Valuation Analysis (What Is the Market Implying from SK Holdings?)
In this insight, we provide a valuation analysis of SK Biopharmaceuticals (BIO SK).Bullish Case Valuation - If we take a bullish case valuation...
480 Views
SK Biopharm IPO Preview
SK Biopharmaceuticals (BIO SK) is getting ready to complete an IPO in the Korean stock market in June. The SK Biopharm will be one of the biggest...
348 Views
U.S. Equity Strategy: Several Indicators Suggest a Pullback Likely
Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight...
544 Views